Merck (MRK) and Sirna (RNAI) Merck Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of Sirna by Merck
More News related to MRK
- Merck (MRK) Declares $0.38 Quarterly Dividend; 4.1% Yield; Announces $3B Common Buyback
- Merck Announces Quarterly Dividends and New $3 Billion Share Repurchase Program
- PROLOR Biotech Reports Merck Receives Positive Regulatory Opinion for European Marketing of Long-Acting CTP-Modified Fertility Treatment ELONVA(R) (FSH-CTP)
- PROLOR Biotech Reports Merck Receives Positive Regulatory Opinion for European Marketing of Long-Acting CTP-Modified Fertility Treatment ELONVA(R) (FSH-CTP)
- Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX(R) (alendronate sodium)
More News related to RNAI
- 52-Week Highs of Note
- Merck (MRK) and Sirna (RNAI) Merck Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of Sirna by Merck
- Sirna Therapeutics (RNAI) Reports a Q3 Loss
- HealthCor Management Sends New Letter to ICOS (ICOS) Opposing Eli Lilly Takeover
- Rodman & Renshaw Bullish on Bioenvision (BIVN), Says Stock Does Not Reflect Clofarabine or Buyout
More News related to Mergers and Acquisitions
- Chaparral Energy and Refining Energy (URX) Amend Merger Agreement
- Mediware (MEDW) to Acquire Healthcare Automation and Advantage Reimbursement for $5.5M
- Dow Chem. (DOW) Subsidiary to Acquire Hyland Seeds; Cowan to Remain General Manager
- Windstream (WIN) to Acquire Iowa Telecom (IWA) for 0.804/Shares Plus $7.90 in Cash; Deal Valued at $1.1B
- Interactive Data Corp. (IDC) to Acquire Dow Jones OFS Data and Tools Assets
Merck & Co., Inc. (NYSE: MRK) and Sirna Therapeutics, Inc. (NASDAQ: RNAI) announced that the federal regulatory antitrust waiting period expired for Merck & Co.'s approximately $1.1 billion acquisition of Sirna Therapeutics. On Oct. 30, 2006, Merck entered into a definitive agreement to acquire Sirna for $13 per share in an all-cash transaction.
Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration, hepatitis C, dermatology, asthma, respiratory syncytial virus and Huntington's disease
Related Categories
Mergers and AcquisitionsStocks Mentioned
-0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
